SOST and osteoporosis: Since inhibition of sclerostin would activate Wnt signaling, and this might benefit bone formation as well as potentially benefit neurons, synaptic plasticity, and microglia, Romosozumab might also be a good candidate for both osteoporosis and ADRD therapy.